This activity was originally presented at the 2025 HOPA Annual Conference in Portland, Oregon.
Program Description
Advances in genetic engineering have led to the development of oncolytic viruses (OVs), which are designed to infect and replicate in cancer cells, causing cell death and release of tumor-specific antigens and neoantigens. Misconceptions about viral transmission risks to healthcare professionals can limit patient access and create logistical hurdles. Pharmacists play a crucial role in biohazard safety committees and educating health care providers about the use and safety of OV therapies. Strategies to help mitigate biohazard risks while supporting safe and effective OV administration will be discussed to prepare oncology pharmacists to safely integrate OVs into clinical practice.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: April 17, 2025
Expiration date: October 17, 2026
Time to complete activity: 1.0 hours
Learner level: Advanced
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Investigate the unique mechanism of action and safety considerations of herpes simplex virus (HSV)-based oncolytic viruses in the treatment of melanoma
- Determine the risk of viral transmission with HSV-based oncolytic vaccines according to recent clinical evidence
- Examine the latest developments in HSV-based oncolytic immunotherapies for melanoma, focusing on their safety profiles and clinical effectiveness
- Employ best practices and biohazard safety protocols to ensure the safe handling of oncolytic HSV-based immunotherapies, minimizing risks to patients and health care providers
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here